Europese Unie - Estlands - EMA (European Medicines Agency)

orchard therapeutics (netherlands) bv - atidarsagene autotemcel - leukodystrophy, metachromatic - muud närvisüsteemi ravimid - libmeldy is indicated for the treatment of metachromatic leukodystrophy (mld) characterized by biallelic mutations in the arysulfatase a (arsa) gene leading to a reduction of the arsa enzymatic activity:in children with late infantile or early juvenile forms, without clinical manifestations of the disease,in children with the early juvenile form, with early clinical manifestations of the disease, who still  have the ability to walk independently and before the onset of cognitive decline.

Estland - Estlands - Ravimiamet

norameda uab - tsiprofloksatsiin - infusioonilahus - 2mg 1ml 100ml 10tk; 2mg 1ml 200ml 10tk

Estland - Estlands - Ravimiamet

krka d.d. novo mesto - amoksitsilliin - dispergeeruv tablett - 1000mg 8tk; 1000mg 16tk; 1000mg 12tk; 1000mg 20tk; 1000mg 6tk

Estland - Estlands - Ravimiamet

krka d.d. novo mesto - amoksitsilliin - dispergeeruv tablett - 750mg 30tk; 750mg 12tk; 750mg 16tk; 750mg 20tk

Europese Unie - Estlands - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - idecabtagene vicleucel - multiple myeloma; neoplasms; cancer; neoplasms, plasma cell; hemostatic disorders; vascular diseases; cardiovascular diseases; paraproteinemias; blood protein disorders; hematologic diseases; hemic and lymphatic diseases; hemorrhagic disorders; infectious mononucleosis; lymphoproliferative disorders; immunoproliferative disorders; immune system diseases - antineoplastilised ained - abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti cd38 antibody and have demonstrated disease progression on the last therapy.

Estland - Estlands - Ravimiamet

ideal trade links uab - trasodoon - toimeainet prolongeeritult vabastav tablett - 150mg 60tk

Europese Unie - Estlands - EMA (European Medicines Agency)

pfizer europe ma eeig  - voxelotor - anemia; anemia, hemolytic; anemia, sickle cell - other hematological agents - oxbryta is indicated for the treatment of haemolytic anaemia due to sickle cell disease (scd) in adults and paediatric patients 12 years of age and older as monotherapy or in combination with hydroxycarbamide.

Estland - Estlands - Ravimiamet

ideal trade links uab - polüstüreensulfonaat - suukaudse/rektaalsuspensiooni pulber - 949mg 1g 500g 1tk

Estland - Estlands - Ravimiamet

first pharma oÜ - trasodoon - toimeainet prolongeeritult vabastav tablett - 150mg 60tk; 150mg 20tk